55I0 Stock Chart & Stats
€14.32
€0.85(6.27%)
At close: 4:00 PM EDT
€14.32
€0.85(6.27%)
Day’s Range― - ―
52-Week Range€12.29 - €26.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.19B
Enterprise Value€5.79K
Total Cash (Recent Filing)€425.30M
Total Debt (Recent Filing)€1.23B
Price to Earnings (P/E)150.0
Beta0.82
Next Earnings
Nov 03, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding243,278,090
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.05
Price to Book (P/B)2.89
Price to Sales (P/S)5.82
P/FCF Ratio50.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.90Price Target Upside45.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.46
Revenue Forecast (FY)€976.31M
Bulls Say, Bears Say
Bulls Say
Cash GenerationMirion's substantial TTM operating cash flow (~$175.8M) and FCF (~$136.8M) with strong year-over-year FCF improvement provide durable internal funding for capex, integration, buybacks and debt reduction. Reliable cash generation supports reinvestment and cushions margin volatility over multiple quarters.
Backlog And Revenue VisibilityA >$1.1B backlog and management's statement that H1 plus backlog covers ~81% of full-year revenue give multi-quarter revenue visibility. This contracted work and order coverage supports predictable project conversion, steady service schedules and durable near-term revenue recognition over the next 2–6 months.
Leadership In Nuclear & SMR DemandStrong growth in nuclear orders and meaningful SMR bookings reflect structural demand drivers—life‑extensions, digital upgrades and SMR deployments. Mirion's depth in nuclear monitoring and systems positions it to capture multi-year project flows and sustain above-market organic growth in this high‑barrier end market.
Bears Say
Heavy Reliance On M&A For GrowthMost recent consolidated growth was driven largely by acquisitions rather than organic demand. Dependence on bolt‑on deals raises sustainability concerns: growth may slow if M&A activity declines, integration can dilute margins, and future earnings volatility may increase absent stronger organic momentum.
Medical Segment Softness (dosimetry Weakness)Persistent weakness in medical and dosimetry reduces recurring revenue from monitoring programs and consumables, which are typically steadier and higher-margin. Prolonged softness in these areas would constrain consolidated organic growth and limit margin expansion over the medium term.
Backlog Conversion And Timing RiskWhile backlog is sizable, management flags that large project timing and government schedules can slip. Delays in converting large awards create structural revenue and margin timing risk, meaning cash flow and profitability can move materially quarter-to-quarter despite apparent backlog strength.
55I0 FAQ
What was Mirion Technologies’s price range in the past 12 months?
Mirion Technologies lowest stock price was €12.29 and its highest was €26.40 in the past 12 months.
What is Mirion Technologies’s market cap?
Mirion Technologies’s market cap is €3.19B.
When is Mirion Technologies’s upcoming earnings report date?
Mirion Technologies’s upcoming earnings report date is Nov 03, 2026 which is in 67 days.
How were Mirion Technologies’s earnings last quarter?
Mirion Technologies released its earnings results on Jul 28, 2026. The company reported €0.103 earnings per share for the quarter, beating the consensus estimate of €0.088 by €0.015.
Is Mirion Technologies overvalued?
According to Wall Street analysts Mirion Technologies’s price is currently Undervalued.
Does Mirion Technologies pay dividends?
Mirion Technologies does not currently pay dividends.
What is Mirion Technologies’s EPS estimate?
Mirion Technologies’s EPS estimate is 0.1.
How many shares outstanding does Mirion Technologies have?
Mirion Technologies has 243,278,090 shares outstanding.
What happened to Mirion Technologies’s price movement after its last earnings report?
Mirion Technologies reported an EPS of €0.103 in its last earnings report, beating expectations of €0.088. Following the earnings report the stock price went up 4.156%.
Which hedge fund is a major shareholder of Mirion Technologies?
Currently, no hedge funds are holding shares in DE:55I0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirion Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€20.90 (45.92% Upside)
€20.90 (45.92% Upside)
Blogger Sentiment
Neutral
DE:55I0 Sentiment 57%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.61%
Trailing 12-Months
Company Description
Mirion Technologies
Mirion Technologies, Inc., established in 2005 and formerly known as Global Monitoring Systems, Inc. until its name change in January 2006, is based in Atlanta, Georgia. The company specializes in providing a comprehensive suite of specialized solutions for radiation detection, measurement, analysis, and monitoring. Its operations span a wide international footprint, covering countries such as the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, the Netherlands, Estonia, and Japan. The business is organized into two distinct operating segments: Medical and Industrial. The Medical segment delivers critical solutions aimed at enhancing patient safety and treatment accuracy within healthcare environments. Offerings here include quality assurance and dosimetry tools for radiation oncology, specialized patient safety systems for diagnostic imaging and radiation therapy centers, and precision calibration and verification solutions for medical imaging and treatment accuracy. Furthermore, it supplies radionuclide therapy products, which encompass shielding, handling equipment, dedicated medical imaging furniture, and rehabilitation aids for nuclear medicine applications. This segment fundamentally supports advancements in medical diagnostics, cancer treatment, professional safety for practitioners, and patient recovery. Conversely, the Industrial segment addresses vital requirements in radiation safety, measurement, and analysis across non-medical industries. It furnishes clients with personal radiation detection devices, identification equipment, and advanced analytical instrumentation. Mirion's extensive product and solution portfolio includes a variety of items such as nuclear medicine preparations, personal dosimeters, contamination and clearance monitoring systems, and sophisticated reactor instrumentation and control equipment. They also provide both medical and industrial imaging systems along with their related accessories, in addition to specialized instruments for alpha spectroscopy, alpha/beta counting, and gamma spectroscopy detector systems. Supplementary offerings include electrical penetration components, cancer diagnostic tools, software solutions, and a range of other services. Mirion serves a broad and varied clientele across numerous sectors. This includes healthcare providers like hospitals, clinics, urgent care facilities, dental and veterinary offices, and specialized radiation treatment centers, as well as original equipment manufacturers (OEMs) for radiation therapy. Beyond healthcare, their customers extend to research laboratories, military organizations, governmental agencies, various industrial enterprises, power and utility companies, reactor design firms, and nuclear power plants (NPPs).
55I0 Company Deck
55I0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum driven by substantial backlog and order growth (notably in nuclear power and SMRs), expanding adjusted EBITDA margins, robust free cash flow, successful integration of Paragon, and maintained full-year guidance with good revenue coverage. Offsetting risks include weak organic revenue (medical softness and dosimetry declines), an $18M China debooking, M&A-related margin dilution, and timing/execution risk on large opportunities. On balance the positive drivers (backlog growth, margin expansion, cash generation, large wins, AI/product innovation) materially outweigh the near-term challenges, supporting constructive outlook for the remainder of 2026.View all DE:55I0 earnings summaries55I0 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€20.90
▲(45.92% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month








